{"id":15058,"date":"2026-08-12T03:09:36","date_gmt":"2026-08-12T10:09:36","guid":{"rendered":"https:\/\/cellpeptides.com\/?post_type=product&#038;p=15058"},"modified":"2026-08-12T03:25:58","modified_gmt":"2026-08-12T10:25:58","slug":"buy-foxo4-dri-2mg","status":"publish","type":"product","link":"https:\/\/cellpeptides.com\/lt\/product\/buy-foxo4-dri-2mg\/","title":{"rendered":"FOXO4-DRI 2mg"},"content":{"rendered":"<h2><span style=\"font-weight: 400;\">Kas yra FOXO4-DRI?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Tai sintetinis peptidas, sudarytas i\u0161 46 aminor\u016bg\u0161\u010di\u0173, visi\u0161kai sudarytas i\u0161 D-aminor\u016bg\u0161\u010di\u0173 atvirk\u0161tine seka. Jis tiekiamas kaip liofilizuoti milteliai laboratoriniams ir tyrim\u0173 tikslams. <\/span><i><span style=\"font-weight: 400;\">tiktai<\/span><\/i><span style=\"font-weight: 400;\">. Vis\u0173 pirma, \u0161is peptidas yra tiriamas d\u0117l selektyvaus senstan\u010di\u0173 l\u0105steli\u0173 \u0161alinimo, nes jis gali nutraukti ry\u0161\u012f su p53 senstan\u010diose l\u0105stel\u0117se, leisdamas joms \u017e\u016bti. Dabar tur\u0117kite omenyje, kad FOXO4-DRI yra tik ikiklinikinio tyrimo stadijoje ir n\u0117ra joki\u0173 su \u017emon\u0117mis susijusi\u0173 duomen\u0173. O dauguma skambi\u0173 teigini\u0173 apie sen\u0117jimo stabdym\u0105 ir \u201czombini\u0173 l\u0105steli\u0173\u201d naikinim\u0105 yra \u0161iek tiek netiksl\u016bs. Pagrindin\u0117 jo taikymo pel\u0117ms i\u0161vada buvo ta, kad jis atk\u016br\u0117 gyvybingum\u0105, kailio tankum\u0105 ir inkst\u0173 veikl\u0105 tiek greitai senstan\u010dioms XpdTTD\/TTD, tiek nat\u016braliai pasenusioms pel\u0117ms. N\u0117 viename tyrime jis neminimas kaip ka\u017ekas, kas \u201catjaunina\u201d.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">DRI rei\u0161kia D-retro-inverso. Tai i\u0161 esm\u0117s rei\u0161kia atvirk\u0161tin\u0119 aminor\u016bg\u0161\u010di\u0173 sek\u0105 arba veidrodin\u012f atvaizd\u0105. Mokslininkai taip apgr\u0119\u017eia sekas tod\u0117l, kad, nors bendras poveikis i\u0161lieka toks pat, suirimas yra nepaprastai sul\u0117tinamas. Kitaip tariant, proteaz\u0117s greitai suvir\u0161kina L-aminor\u016bg\u0161\u010di\u0173 peptidus, o \u0161i veidrodinio atvaizdo \/ atvirk\u0161tin\u0117s sekos taktika i\u0161saugo \u0161onin\u0117s grandin\u0117s topografij\u0105 (kad ji vis tiek gal\u0117t\u0173 normaliai jungtis) ir kartu yra atspari suirimui.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">FOXO4 baltymo p53 s\u0105veikos sritis buvo tirta, o \u0161io peptido DRI variant\u0105 gavo Baar su kolegomis de Keizer labaratorijoje (Cell, 2017). Peptidas turi l\u0105stel\u0119 skverbiantis uodeg\u0105, leid\u017eian\u010di\u0105 jam pereiti l\u0105stel\u0117s membranas.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Kaip veikia FOXO4-DRI?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Did\u017eioji dalis to, kaip veikia peptidai, priklauso nuo receptori\u0173. Ir \u010dia yra lygiai taip pat. Bet pirmiausia \u017eenklime \u017eingsn\u012f atgal.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Senstan\u010dios l\u0105stel\u0117s vadinamos sen\u0117jusiomis l\u0105stel\u0117mis. \u0160ios l\u0105stel\u0117s nustojo dalytis, yra didel\u0117s ir da\u017enai gali i\u0161skirti kenksmingas u\u017edegimines chemines med\u017eiagas bei net pa\u017eeisti aplinkinius audinius. \u0160iose l\u0105stel\u0117se kaupiasi baltymas, vadinamas FOXO4. Be to, l\u0105stel\u0117ms patyrus radiacijos sukelt\u0105 sen\u0117jim\u0105 (pavyzd\u017eiui, chemoterapijos metu), jose susikaupia daug FOXO4. FOXO4 paskirtis yra u\u017ekirsti keli\u0105 apoptozei \u0161iose sen\u0117jan\u010diose l\u0105stel\u0117se. Jei gal\u0117tum\u0117te slopinti FOXO4 rai\u0161k\u0105, nat\u016braliai pasteb\u0117tum\u0117te, kad daugiau \u0161i\u0173 sen\u0117jan\u010di\u0173 l\u0105steli\u0173 \u017e\u016bsta.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Tai, k\u0105 FOXO4 daro senstan\u010dioje l\u0105stel\u0117je, yra p53 \u2013 baltymo, turin\u010dio daug funkcij\u0173, i\u0161 kuri\u0173 viena yra si\u0173sti l\u0105stel\u0117s \u017e\u016bt\u012f skatinan\u010dius signalus, kad l\u0105stel\u0117 gal\u0117t\u0173 mirti \u2013 sulaikymas. Kol didelis kiekis FOXO4 sulaiko vis\u0105 t\u0105 p53 sen\u0117jan\u010diose l\u0105stel\u0117se, jos nemirs.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Sintetinis peptidas, vadinamas FOXO4-DRI, apie kur\u012f \u010dia kalbame, konkuruoja d\u0117l jungimosi vietos. Jis bando prisijungti prie p53 pirmas, ankstesnis u\u017e pa\u010dios l\u0105stel\u0117s FOXO4. Ir jam tai sekasi gana s\u0117kmingai. Buvo pasteb\u0117ta, kad peptidas turi didesn\u0119 afinitet\u0105 p53. Dabar, kadangi nat\u016bral\u0173 FOXO4\/p53 ry\u0161\u012f pakeit\u0117me FOXO4-DRI\/p53 ry\u0161iu, i\u0161 esm\u0117s sustabd\u0117me p53 prisijungim\u0105 prie branduolio. Jis gali i\u0161eiti ir si\u0173sti l\u0105stel\u0117s \u017e\u016bties signalus, nes peptidas FOXO4-DRI to slopina.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Taigi, tiesiog prisijung\u0119s prie p53 pirm\u0105j\u012f, anks\u010diau u\u017e nat\u016bral\u0173 FOXO4, peptidas leid\u017eia senstan\u010dioms l\u0105stel\u0117ms mirti. Kadangi p n\u0117ra prijungtas prie nat\u016braliojo FOXO4 (kuris laiko j\u012f branduolyje), jis keliauja \u012f mitochondrijas ir sukelia apoptoz\u0119. Tai savo ruo\u017etu visi\u0161kai sunaikina senstan\u010di\u0105 l\u0105stel\u0119.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u0160is peptidas i\u0161 prigimties yra selektyvus, nes daugumoje sveik\u0173 suaugusi\u0173j\u0173 l\u0105steli\u0173 FOXO4 kiekis yra ma\u017eas. Jis padid\u0117ja tik senstan\u010diose l\u0105stel\u0117se.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">FOXO4-p53 s\u0105veika<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Kod\u0117l pa\u017eeistos l\u0105stel\u0117s atsisako mirti? Paprastai d\u0117l susikaupusi\u0173 DNR pa\u017eeidim\u0173 l\u0105stel\u0117 pasuka arba link apoptoz\u0117s, arba link sen\u0117jimo. Senstan\u010dios l\u0105stel\u0117s pasirinko antr\u0105j\u012f variant\u0105 ir privalo toliau ginti \u0161\u012f pasirinkim\u0105, tod\u0117l jos gyvena toliau. \u017dvelgiant kitaip, tai yra atsparumas apoptozei. \u0160is atsparumas pasirei\u0161kia per daugel\u012f dalyk\u0173. Jos yra pasirengusios mirti, bet vis tiek laikosi. FOXO4 baltymas, izoliuojantis p53, yra vienas i\u0161 mechanizm\u0173, palaikan\u010di\u0173 \u0161\u012f laikym\u0105si.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Nat\u016bralu, kad FOXO4 rasta padid\u0117jusio kiekio senstan\u010diose l\u0105stel\u0117se ir yra kritinis komponentas palaikant l\u0105steli\u0173 gyvybingum\u0105. Jis sulaiko p53 branduolyje, kuris kitu atveju si\u0173st\u0173 signal\u0105 apoptozei.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">FOXO4-DRI ir senstantys l\u0105stel\u0117s: kam jos naudojamos?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Senescencija \u2013 tai nuolatin\u0117 l\u0105stel\u0117s dalijimosi sustabdymo b\u016bsena. L\u0105stel\u0117 yra pasirengusi mirti, bet laikosi \u2013 i\u0161lieka metaboli\u0161kai aktyvi ir taip pat sekretuoja. \u0160ios l\u0105stel\u0117s i\u0161vysto su senescencija susijus\u012f sekretorin\u012f fenotip\u0105 \u2013 nuolatin\u012f prozin\u0117tin\u012f fenotip\u0105, gal Cia prisidedant\u012f prie pagreitinto sen\u0117jimo ir chemotoksi\u0161kumo.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Tyrimai nuo 2011 met\u0173 parod\u0117, kad pa\u0161alinus sen\u0117jan\u010dias l\u0105steles galima u\u017ekirsti keli\u0105 audini\u0173 disfunkcijai arba j\u0105 atitolinti, ir kad sen\u0117jan\u010dios l\u0105stel\u0117s u\u017eima sveik\u0173 l\u0105steli\u0173 viet\u0105, o nepa\u0161alintos sutrikdo vietin\u0119 veikl\u0105. Tad kod\u0117l tai i\u0161vis vyksta? Na, sen\u0117jimas n\u0117ra vienodai blogas. L\u0105steli\u0173 sen\u0117jimas yra dvejopo pob\u016bd\u017eio \u2013 embriono vystymosi, audini\u0173 atstatymo ir augli\u0173 slopinimo metu jis i\u0161 tikr\u0173j\u0173 yra naudingas. Ta\u010diau jis yra \u017ealingas esant l\u0117tiniam stresui, nuolatiniam audini\u0173 pa\u017eeidimui ir sutrikusiam \u0161alinimui.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">L\u0105steli\u0173 sen\u0117jimo tyrimai<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">FOXO4-DRI daugiausia tiriamas kaip eksperimentinis senolitinis peptidas, besiskiriantis nuo ma\u017e\u0173 molekuli\u0173 senolitik\u0173. Pradiniame in-vitro modelyje buvo naudojami jonizuojan\u010diosios radiacijos pa\u017eeisti senstantys IMR90 \u017emogaus fibroblastai. Pagrindinis rezultatas? Puikus selektyvumas. Be to, daugelis v\u0117lesni\u0173 grupi\u0173 naudojo peptid\u0105 kaip zond\u0105 \u012fvairi\u0173 tip\u0173 l\u0105stel\u0117se \u2013 nuo IMR90 fibroblast\u0173 ir TM3 Leydig l\u0105steli\u0173 iki chondrocit\u0173, endotelio l\u0105steli\u0173 ir plau\u010di\u0173 fibroblast\u0173.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Su am\u017eiumi susijusi\u0173 funkcij\u0173 tyrimai<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Tyrimai su gyv\u016bnais parod\u0117, kad tai pagerina fizin\u012f aktyvum\u0105, kailio b\u016bkl\u0119, inkst\u0173 \u017eymenis ir audini\u0173 veikl\u0105. Pradiniame darb\u0173 rinkinyje yra du pagrindiniai modeliai: greitai senstanti DNR atstatymo defekt\u0173 turinti linija ir nat\u016braliai pasenusios pel\u0117s. Rezultatai buvo nuosekl\u016bs abiem atvejais. B\u0117gimo ratelio aktyvumas ir kailio \u012fvertinimas buvo vertinami 26 savai\u010di\u0173 am\u017eiaus laukinio tipo ir XpdTTD\/TTD pel\u0117ms, o nub\u0117gtas atstumas matuotas kilometrais per dien\u0105. Tyrimas taip pat prane\u0161\u0117 apie suma\u017e\u0117jus\u012f savaime atsirandant\u012f inkst\u0173 glomeruloskleroz\u0119 ir pager\u0117jus\u012f inkst\u0173 filtravimo paj\u0117gum\u0105 greitai senstan\u010dioms pel\u0117ms.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Reprodukcinio sen\u0117jimo tyrimai<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Buvo atlikti du atskiri Kinijos moksliniai tyrimai, kuriuos atliko ta pati grup\u0117. Pirmajame (Zhang ir kt., 2020 m.) pager\u0117j\u0119 \u017eymenys parod\u0117 padid\u0117jus\u012f testosterono kiek\u012f serumas, padid\u0117jus\u012f 3\u03b2-HSD ir CYP11A1, suma\u017e\u0117jus\u012f intersticini\u0173 l\u0105steli\u0173 SA-\u03b2-gal aktyvum\u0105, ma\u017eesn\u012f p53, p21 ir p16 kiek\u012f bei suma\u017e\u0117jus\u012f IL-1\u03b2, IL-6 ir TGF-\u03b2. Antrasis tyrimas (Li ir kt., 2024 m.) pasi\u017eym\u0117jo kitu dizainu ir ilgesne poveikio trukme. Prane\u0161ti rezultatai \u2013 pager\u0117jusi spermos kokyb\u0117 ir geresn\u0117 spermatogenez\u0117 sen pel\u0117ms, o si\u016blomas mechanizmas \u2013 suma\u017e\u0117jusi SASP sekrecija i\u0161 Leydig l\u0105steli\u0173.\u00a0<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Fibroz\u0117 ir audini\u0173 tyrimai<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Tyr\u0117jai taip pat i\u0161tyr\u0117 FOXO4-DRI eksperimentiniuose plau\u010di\u0173 fibroz\u0117s, kremzli\u0173 ir kraujagysli\u0173 sen\u0117jimo modeliuose.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Plau\u010di\u0173 fibroz\u0117<\/b><span style=\"font-weight: 400;\">Pel\u0117s bleomicino indukuotame plau\u010di\u0173 fibroz\u0117s modelyje FOXO4-DRI suma\u017eino senenejan\u010di\u0173 l\u0105steli\u0173 skai\u010di\u0173, suma\u017eino SASP rai\u0161k\u0105 ir susilpnino bleomicino indukuotus morfologinius poky\u010dius bei kolageno nus\u0117dim\u0105, prilygdamas patvirtintam vaistui pirfenidonui; jis taip pat padidino 2 tipo alveolini\u0173 epitelio l\u0105steli\u0173 ir fibroblast\u0173 procentin\u0119 dal\u012f bei suma\u017eino miofibroblast\u0173 skai\u010di\u0173, o in vitro parod\u0117 tendencij\u0105 naikinti TGF-\u03b2 indukuotus miofibroblastus<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Kremzl\u0117<\/b><span style=\"font-weight: 400;\">\u017dmogaus chondrocitai buvo padauginti iki 9 populiacijos dvigub\u0117jimo lygio, kad b\u016bt\u0173 imituojamos l\u0105stel\u0117s, paruo\u0161tos autologinei chondrocit\u0173 implantacijai, o PDL3 naudotas kaip minimaliai padaugintas kontrolinis m\u0117ginys. FOXO4-DRI pa\u0161alino daugiau nei pus\u0119 PDL9 l\u0105steli\u0173, reik\u0161mingai nepaveikdamas PDL3 l\u0105steli\u0173 skai\u010diaus, ir reik\u0161mingai suma\u017eino sen\u0117jimo lyg\u012f PDL9. I\u0161ankstinis apdorojimas nepadidino PDL9 chondrocit\u0173 chondrogeninio potencialo, nors i\u0161 i\u0161 anksto apdorot\u0173 l\u0105steli\u0173 suformuotas kremzl\u0117s audinys pasi\u017eym\u0117jo ma\u017eesne su sen\u0117jimu susijusi\u0173 sekretuot\u0173 veiksni\u0173 apykaita.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Kraujagysli\u0173 sen\u0117jimas<\/b><span style=\"font-weight: 400;\">Tai naujausias darbas. 2026 m. tyrimas prane\u0161a, kad FOXO4-DRI sukelia apoptoz\u0119 senstan\u010diose endotelio l\u0105stel\u0117se, aktyvindamas p53\/BCL-2\/Caspase-3 keli\u0105, ir pagerina kraujagysli\u0173 funkcij\u0105 bei atitolina kraujagysli\u0173 sen\u0117jim\u0105<\/span><\/li>\n<\/ul>\n<h2><span style=\"font-weight: 400;\">FOXO4-DRI palyginti su kitais senolitikais<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Tiesiogin\u0117 \u201calternatyva\u201d neegzistuoja, ta\u010diau keli skirtingi mechanizmai veikia skirtingus senestuojan\u010di\u0173 l\u0105steli\u0173 antiapoptozinius kelian\u010dius kelius, kuriuos galima ma\u017edaug palyginti. Taip pat nepamir\u0161kite, kad skirtingi senestuojan\u010di\u0173 l\u0105steli\u0173 tipai reaguoja \u012f skirtingas med\u017eiagas. Tod\u0117l jos n\u0117ra kei\u010diamos tarpusavyje. N\u0117 vienas i\u0161 j\u0173 i\u0161 prigimties n\u0117ra prana\u0161esnis.<\/span><\/p>\n<table>\n<tbody>\n<tr>\n<td><\/td>\n<td><b>FOXO4-DRI<\/b><\/td>\n<td><b>Dasatinitas + Kvercetinas<\/b><\/td>\n<td><b>Fisetinas<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>Klas\u0117<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Sintetinis D-retretro-inverso peptidas<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Kinaz\u0117s inhibitorius ir flavonoidas, vartojamas per burn\u0105<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Flavonoidas, vartojamas per burn\u0105<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>Mechanizmas<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Sutrikdo vien\u0105 specifin\u0119 baltym\u0173 ir baltym\u0173 s\u0105veik\u0105 (FOXO4-p53)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Laikinai i\u0161jungia pro-i\u0161gyvenimo tinklus, saugan\u010dius senstan\u010dias l\u0105steles<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Platus flavonoid\u0173 senolitinis aktyvumas<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>Pristatymas<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Injekcinis vaistas su gyv\u016bn\u0173 tyrimais<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u017dodinis<\/span><\/td>\n<td><span style=\"font-weight: 400;\">\u017dodinis<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>\u017dmoni\u0173 duomenys<\/b><\/td>\n<td><span style=\"font-weight: 400;\">N\u0117ra<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Ankstyvosios stadijos bandomieji tyrimai<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Vyksta tyrimai<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<h2><span style=\"font-weight: 400;\">FOXO4-DRI dozavimo protokolai moksliniuose tyrimuose, biohakavime ir \u201eReddit\u201c prane\u0161imuose<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">\u017demiau pateikti skai\u010diai yra gyv\u016bn\u0173 ir l\u0105steli\u0173 kult\u016bros parametrai, u\u017efiksuoti siekiant u\u017etikrinti atkuriamum\u0105 laboratorin\u0117se s\u0105lygomis. N\u0117ra nustatytos doz\u0117s \u017emon\u0117ms, saugumo duomen\u0173 su \u017emon\u0117mis, veiksmingumo duomen\u0173 su \u017emon\u0117mis ir jokio patvirtinto b\u016bdo gyv\u016bn\u0173 mg\/kg rodikl\u012f paversti rodikliu \u017emogui.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Paskelbti tyrim\u0173 protokolai<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Literat\u016broje \u012fprasta taikyti protarpin\u012f, trumpalaik\u012f dozavim\u0105, ta\u010diau \u0161iam peptidui n\u0117ra paskelbta joki\u0173 doz\u0117s ir atsako arba doz\u0117s optimizavimo tyrim\u0173. Pateikiami tyrimai ir juose naudoti dozavimo b\u016bdai:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Baar ir kt. 2027, Cell: Ap\u0161vitinti IMR90 fibroblastai in vitro, doksorubicinu paveiktos pel\u0117s, greitai senstan\u010dios XpdTTD\/TTD pel\u0117s, nat\u016braliai pasenusios pel\u0117s. 4\u20135 laukinio tipo arba XpdTTD\/TTD pel\u0117s, 0, 2 ir 4 dienomis intravenous injection b\u016bdu paveiktos 5 mg\/kg FOXO4-DRI, kraujo m\u0117ginys paimtas pra\u0117jus 28 dienoms po pirmosios injekcijos, o chemotoksinio tyrimo atveju \u2013 viena doksorubicino doz\u0117 10 mg\/kg i.p., po kurios seka FOXO4-DRI po 4 x 10 mg\/kg i.v., plius antrasis eksperimentas naudojant dvi doksorubicino dozes, po kuri\u0173 seka FOXO4-DRI po 3 x 5 mg\/kg su viena diena pertraukos.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Zhang ir kt., 2020, Sen\u0117jimas: Nat\u016braliai pasen\u0119 20\u201324 m\u0117nesi\u0173 am\u017eiaus pel\u0117s, 5 mg\/kg PBS, intraperitoniniu b\u016bdu, kas antr\u0105 dien\u0105, trys su\u0161virk\u0161timai.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Huang ir kt. 2021, Front Bioeng Biotechnol.: Tik in vitro, \u017emogaus chondrocitai, esant PDL9, palyginti su PDL3.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Han ir kt. 2022, J Cell Mol Med.: 6\u20138 savai\u010di\u0173 am\u017eiaus patinai C57BL\/6J pel\u0117s, peptidas praskiestas iki 1 mg\/mL PBS prie\u0161 intraperitorin\u0119 injekcij\u0105.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Li ir kt., 2024 m., Exp Gerontol.: 20 m\u0117nesi\u0173 am\u017eiaus pel\u0117s, 5 mg\/kg per par\u0105 intraperitoniniu b\u016bdu 30 dien\u0173.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Hu ir kt. 2026, Front Bioeng Biotechnol.: 17 m\u0117nesi\u0173 am\u017eiaus pel\u0117s, 5 mg\/kg intraperitoni\u0161kai kas 2 dienas 1 m\u0117nes\u012f.<\/span><\/li>\n<\/ul>\n<h3><span style=\"font-weight: 400;\">Biohakingas ir \u201eReddit\u201c prane\u0161imai<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">D\u0117l \u0161io peptido tikrai kyla tam tikr\u0173 diskusij\u0173, ta\u010diau joki\u0173 toliau nurodyt\u0173 dalyk\u0173 negalima atkurti kaip protokolo. Forumuose ir pardav\u0117j\u0173 tinklara\u0161\u010diuose sklando daugyb\u0117 savaranki\u0161ko eksperimentavimo prane\u0161im\u0173, ir jie visi yra nekontroliuojami bei pagr\u012fsti asmenine patirtimi. N\u0117 viename i\u0161 j\u0173 n\u0117ra jokio nepriklausomo junginio tapatyb\u0117s, grynumo ar rezultato patvirtinimo.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Be to, tai yra pel\u0117s doz\u0117s perskai\u010diavimai pagal k\u016bno svor\u012f be jokio tarpr\u016b\u0161inio perskai\u010diavimo koeficiento, be farmakokinetikos duomen\u0173 ir be toksikologijos.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Apskritai, daugelis socialini\u0173 tinkl\u0173 asmenybi\u0173 ir toki\u0173 \u201esubreddit\u201c bendruomeni\u0173 kaip r\/Biohack_Blueprint, r\/Peptides ir kt. pateikia vartotoj\u0173 atsiliepimus apie tai, su kuo \u017emon\u0117s eksperimentavo. Atlik\u0119 i\u0161sami\u0105 ap\u017evalg\u0105, neradome joki\u0173 nuosekliai ger\u0173 dozi\u0173. \u010cia i\u0161\u0161\u016bkis yra realus \u2013 \u017emon\u0117s tiesiog ne\u017eino, kaip ekstrapoliuoti FOXO4-DRI. Yra pavieni\u0173 i\u0161sami\u0173 sav\u0119s eksperiment\u0173, ta\u010diau juose da\u017enai tr\u016bksta tinkamo ataskait\u0173 teikimo. Didel\u0117 biohakingo bendruomen\u0117s dalis abejoja d\u0117l dozavimo aptarimo FOXO4-DRI atveju, o daugelis biohakeri\u0173 tiesiog gr\u012f\u017eta prie kit\u0173 peptid\u0173, kai reikia nustatyti dozes arba derinti FOXO4-DRI.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Paruo\u0161imas ir laikymas<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">\u0160tai kaip paruo\u0161ti ir laikyti tyrimams skirt\u0105 FOXO4-DRI:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Jis parduodamas kaip liofilizuoti milteliai. Laikykite v\u0117sioje, tamsioje vietoje, kambario temperat\u016broje arba \u0161aldiklyje, kurio temperat\u016bra yra -20\u00b0C arba \u017eemesn\u0117. Venkite u\u017e\u0161aldymo-atitirpimo cikl\u0173. Saugokite nuo \u0161viesos ir dr\u0117gm\u0117s. Tinkamumo laikas paprastai yra 2 metai nuo pagaminimo. Atitirpinus (paruo\u0161us tirpal\u0105), tirpal\u0105 laikykite \u0161aldytuve 2-8\u00b0C temperat\u016broje (tinka ~4 savaites).<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Prie\u0161 nulau\u017eiant sandarikl\u012f, sandar\u0173 flakon\u0105 palaikykite kambario temperat\u016broje, kad ant milteli\u0173 nesikondensuot\u0173 aplinkos dr\u0117gm\u0117.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Skiedikl\u012f l\u0117tai pilkite vidine flakono sienele, o ne tiesiai ant milteli\u0173 tablet\u0117s.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Mai\u0161ymas. \u0160velniai pasukite arba leiskite i\u0161tirpti be judesi\u0173. Niekada neplakite s\u016bkuriu ir nekratykite. Mechanin\u0117 \u0161lytis ir putojimas ardo ilgus peptidus.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Padalykite \u012f vienkartinio naudojimo t\u016brius paruo\u0161imo metu, kad darbinis tirpalas neb\u016bt\u0173 v\u0117l u\u017e\u0161aldytas. Pakartotiniai u\u017e\u0161aldymo ir at\u0161ildymo ciklai yra pagrindin\u0117 i\u0161vengiama aktyvumo praradimo prie\u017eastis.<\/span><\/li>\n<\/ul>\n<h2><span style=\"font-weight: 400;\">FOXO4-DRI DUK<\/span><\/h2>\n<h3><span style=\"font-weight: 400;\">Senestuojan\u010dios l\u0105stel\u0117s<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Suimtos, bet gyvos, vis dar i\u0161skirian\u010dios med\u017eiagas. L\u0105stel\u0117s, kurios i\u0161 esm\u0117s laikosi \u012fsikibusios ir prie\u0161inasi apoptozei.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Kas yra FOXO4-p53 takas ir kod\u0117l tai svarbu \u010dia?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">FOXO4 yra baltymas, kuris jungiasi prie p53 \u2013 kito l\u0105stel\u0117je esan\u010dio baltymo. Tada jis \u201claiko\u201d p53 branduolyje. Tai neleid\u017eia p53 keliauti \u012f mitochondrijas ir si\u0173sti signalo apie apoptoz\u0119 (l\u0105stel\u0117s savi\u017eudyb\u0119). Taip senstan\u010dios l\u0105stel\u0117s prie\u0161inasi mirtim, nors jos neb\u0117ra dalijasi ir yra pasiruo\u0161usios mirti.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Ar FOXO4-DRI buvo i\u0161bandytas su \u017emon\u0117mis?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Ne. Be to, kurianti \u012fmon\u0117 ir kilm\u0117s laboratorija pereina prie naujos kartos jungini\u0173 su geresniais saugos profiliais.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Kuo jis skiriasi nuo geriam\u0173j\u0173 senolitik\u0173, toki\u0173 kaip fizetinas ar kvercetinas?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Skirtingas mechanizmas, kitoks pristatymas ir, kitaip nei tie, n\u0117ra joki\u0173 su \u017emon\u0117mis atlikt\u0173 klinikini\u0173 tyrim\u0173 duomen\u0173. \u017di\u016br\u0117kite auk\u0161\u010diau esant\u012f skyri\u0173 \u201cFOXO4-DRI vs Kiti senolitikai\u201d.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Kod\u0117l atrankumas yra tyrimo klausimas, o ne nusistov\u0117j\u0119s faktas?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Kadangi tai priklauso nuo to, kad FOXO4 kiekis yra padid\u0117j\u0119s senstan\u010diose l\u0105stel\u0117se ir ma\u017eas kitur, kadangi kai kurios senstan\u010di\u0173 l\u0105steli\u0173 populiacijos atlieka apsaugines funkcijas, ir kadangi bent viename tyrime nustatyta, kad senolitinis pa\u0161alinimas pablogino rezultatus tam tikrame kraujagysli\u0173 kontekste.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Kam skirtas \u0161is produktas?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Skirta tik laboratoriniams tyrimams. Neskirta naudoti \u017emon\u0117ms ar veterinariniams tikslams, n\u0117ra maisto papildas, n\u0117ra vaistas, nenaudojama diagnostikai ar gydymui.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><span style=\"font-weight: 400;\">Studijos<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Tikslin\u0117 senstan\u010di\u0173 l\u0105steli\u0173 apoptoz\u0117 atstato audini\u0173 homeostaz\u0119 reaguojant \u012f chemotoksin\u012f poveik\u012f ir sen\u0117jim\u0105 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28340339\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/28340339\/\u00a0<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">P16Ink4a teigiam\u0173 senechcini\u0173 l\u0105steli\u0173 pa\u0161alinimas atitolina su sen\u0117jimu susijusius sutrikimus <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22048312\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/22048312\/\u00a0<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">Su sen\u0117jimu susij\u0119s sekretorinis fenotipas: tamsioji navik\u0173 slopinimo pus\u0117 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20078217\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/20078217\/<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">FOXO4-DRI palengvina su am\u017eiumi susijus\u012f testosterono sekrecijos nepakankamum\u0105, veikdamas senstan\u010dias Leidingo l\u0105steles seniems pel\u0117ms <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7053614\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7053614\/<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">Senolitinis peptidas FOXO4-DRI selektyviai \u0161alina senstan\u010dias l\u0105steles i\u0161 *in vitro* i\u0161pl\u0117st\u0173 \u017emogaus chondrocit\u0173 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33996787\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/33996787\/\u00a0<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">FOXO4 peptidas taikomi miofibroblastams pagerina bleomicino sukelt\u0105 plau\u010di\u0173 fibroz\u0119 pel\u0117se per ECM-receptori\u0173 s\u0105veikos keli\u0105 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35510614\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/35510614\/\u00a0<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">FOXO4-DRI pagerina espermatogenez\u0119 senoms pel\u0117ms, suma\u017eindamas su sen\u0117jimu susijusio sekrecijos fenotipo sekrecij\u0105 i\u0161 Leydig l\u0105steli\u0173<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39025385\/\" target=\"_blank\" rel=\"noopener\"> https:\/\/pubmed.ncbi.nlm.nih.gov\/39025385\/<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">FOXO4-DRI reguliuoja endotelio l\u0105steli\u0173 sen\u0117jim\u0105 per P53 signalin\u012f keli\u0105 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41625068\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/41625068\/\u00a0<\/a><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p><span style=\"font-weight: 400;\"><strong>FOXO4<\/strong> yra l\u0105stel\u0117je prie p53 prisijungiantis baltymas, kuris blokuoja pro-mirtinius signalus senstan\u010diose (senescentin\u0117se) l\u0105stel\u0117se. Tai i\u0161 esm\u0117s neleid\u017eia senstan\u010dioms l\u0105stel\u0117ms mirti. Prisijung\u0119s FOXO4 neleid\u017eia p53 i\u0161skirti signal\u0173, toki\u0173 kaip BAX, kurie sukelt\u0173 l\u0105stel\u0117s savi\u017eudyb\u0119 (apoptoz\u0119). <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Bet jei gal\u0117tum\u0117te nutraukti \u0161\u012f ry\u0161\u012f, l\u0105stel\u0117 dabar gal\u0117t\u0173 laisvai i\u0161skirti l\u0105stel\u0117s mirties signalus. FOXO4-DRI yra peptidas, kuris daro b\u016btent tai \u2013 jis nutraukia t\u0105 ry\u0161\u012f. Tai savo ruo\u017etu priver\u010dia p53 pasi\u0161alinti i\u0161 branduolio ir taip veiksmingai sunaikina senstan\u010dias l\u0105steles. D\u0117l \u0161ios prie\u017easties FOXO4-DRI yra tiriamas d\u0117l jo sen\u0117jim\u0105 stabdan\u010dio poveikio pel\u0117ms (klinikini\u0173 tyrim\u0173 su \u017emon\u0117mis duomen\u0173 n\u0117ra).<\/span><\/p>","protected":false},"featured_media":15060,"template":"","meta":{"_acf_changed":false,"ub_ctt_via":""},"product_brand":[],"product_cat":[52,46,54],"product_tag":[],"class_list":["post-15058","product","type-product","status-publish","has-post-thumbnail","product_cat-anti-inflammatory-response-research-peptides","product_cat-peptides-for-longevity-research","product_cat-peptides-for-tissue-healing-research","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Buy FOXO4-DRI 2mg (99% Purity) - CellPeptides<\/title>\n<meta name=\"description\" content=\"Buy FOXO4-DRI for senescence and longevity research, 99% purity, HPLC-tested. Click here to check availability and order today.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cellpeptides.com\/lt\/product\/buy-tesamorelin-5mg\/\" \/>\n<meta property=\"og:locale\" content=\"lt_LT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Buy FOXO4-DRI 2mg (99% Purity) - CellPeptides\" \/>\n<meta property=\"og:description\" content=\"Buy FOXO4-DRI for senescence and longevity research, 99% purity, HPLC-tested. Click here to check availability and order today.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cellpeptides.com\/lt\/product\/buy-tesamorelin-5mg\/\" \/>\n<meta property=\"og:site_name\" content=\"CellPeptides\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-12T10:25:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2026\/08\/FOXO4-DRI-2mg_mockup.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minu\u010di\u0173\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cellpeptides.com\/product\/buy-foxo4-dri-2mg\/\",\"url\":\"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/\",\"name\":\"Buy FOXO4-DRI 2mg (99% Purity) - CellPeptides\",\"isPartOf\":{\"@id\":\"https:\/\/cellpeptides.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2026\/08\/FOXO4-DRI-2mg_mockup.png\",\"datePublished\":\"2026-08-12T10:09:36+00:00\",\"dateModified\":\"2026-08-12T10:25:58+00:00\",\"description\":\"Buy FOXO4-DRI for senescence and longevity research, 99% purity, HPLC-tested. Click here to check availability and order today.\",\"breadcrumb\":{\"@id\":\"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/#breadcrumb\"},\"inLanguage\":\"lt-LT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"lt-LT\",\"@id\":\"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/#primaryimage\",\"url\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2026\/08\/FOXO4-DRI-2mg_mockup.png\",\"contentUrl\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2026\/08\/FOXO4-DRI-2mg_mockup.png\",\"width\":1200,\"height\":1200,\"caption\":\"FOXO4-DRI 2mg_mockup\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cellpeptides.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shop\",\"item\":\"https:\/\/cellpeptides.com\/shop\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FOXO4-DRI 2mg\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cellpeptides.com\/#website\",\"url\":\"https:\/\/cellpeptides.com\/\",\"name\":\"CellPeptides\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/cellpeptides.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cellpeptides.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"lt-LT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cellpeptides.com\/#organization\",\"name\":\"CellPeptides\",\"url\":\"https:\/\/cellpeptides.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"lt-LT\",\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"contentUrl\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"width\":697,\"height\":152,\"caption\":\"CellPeptides\"},\"image\":{\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pirkite FOXO4-DRI 2 mg (grynumas 99%) \u2013 \u201eCellPeptides\u201c","description":"\u012esigykite FOXO4-DRI sen\u0117jimo ir ilgaam\u017ei\u0161kumo tyrimams, grynumas 99%, patikrintas HPLC metodu. Spauskite \u010dia, kad patikrintum\u0117te, ar prek\u0117 yra sand\u0117lyje, ir u\u017esisakykite jau \u0161iandien.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cellpeptides.com\/lt\/product\/buy-tesamorelin-5mg\/","og_locale":"lt_LT","og_type":"article","og_title":"Buy FOXO4-DRI 2mg (99% Purity) - CellPeptides","og_description":"Buy FOXO4-DRI for senescence and longevity research, 99% purity, HPLC-tested. Click here to check availability and order today.","og_url":"https:\/\/cellpeptides.com\/lt\/product\/buy-tesamorelin-5mg\/","og_site_name":"CellPeptides","article_modified_time":"2026-08-12T10:25:58+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2026\/08\/FOXO4-DRI-2mg_mockup.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minu\u010di\u0173"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cellpeptides.com\/product\/buy-foxo4-dri-2mg\/","url":"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/","name":"Pirkite FOXO4-DRI 2 mg (grynumas 99%) \u2013 \u201eCellPeptides\u201c","isPartOf":{"@id":"https:\/\/cellpeptides.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/#primaryimage"},"image":{"@id":"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/#primaryimage"},"thumbnailUrl":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2026\/08\/FOXO4-DRI-2mg_mockup.png","datePublished":"2026-08-12T10:09:36+00:00","dateModified":"2026-08-12T10:25:58+00:00","description":"\u012esigykite FOXO4-DRI sen\u0117jimo ir ilgaam\u017ei\u0161kumo tyrimams, grynumas 99%, patikrintas HPLC metodu. Spauskite \u010dia, kad patikrintum\u0117te, ar prek\u0117 yra sand\u0117lyje, ir u\u017esisakykite jau \u0161iandien.","breadcrumb":{"@id":"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/#breadcrumb"},"inLanguage":"lt-LT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/"]}]},{"@type":"ImageObject","inLanguage":"lt-LT","@id":"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/#primaryimage","url":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2026\/08\/FOXO4-DRI-2mg_mockup.png","contentUrl":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2026\/08\/FOXO4-DRI-2mg_mockup.png","width":1200,"height":1200,"caption":"FOXO4-DRI 2mg_mockup"},{"@type":"BreadcrumbList","@id":"https:\/\/cellpeptides.com\/product\/buy-tesamorelin-5mg\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cellpeptides.com\/"},{"@type":"ListItem","position":2,"name":"Shop","item":"https:\/\/cellpeptides.com\/shop\/"},{"@type":"ListItem","position":3,"name":"FOXO4-DRI 2mg"}]},{"@type":"WebSite","@id":"https:\/\/cellpeptides.com\/#website","url":"https:\/\/cellpeptides.com\/","name":"L\u0105steli\u0173 peptidai","description":"","publisher":{"@id":"https:\/\/cellpeptides.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cellpeptides.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"lt-LT"},{"@type":"Organization","@id":"https:\/\/cellpeptides.com\/#organization","name":"L\u0105steli\u0173 peptidai","url":"https:\/\/cellpeptides.com\/","logo":{"@type":"ImageObject","inLanguage":"lt-LT","@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/","url":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","contentUrl":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","width":697,"height":152,"caption":"CellPeptides"},"image":{"@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/product\/15058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/types\/product"}],"version-history":[{"count":0,"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/product\/15058\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/media\/15060"}],"wp:attachment":[{"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/media?parent=15058"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/product_brand?post=15058"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/product_cat?post=15058"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/product_tag?post=15058"}],"curies":[{"name":"gerai \u017eaista","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}